Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gisadenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.88 |
| ▸ | PDE6C | P51160 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gisadenafil SCHEMBL29478482 | 1.00 | PDE5A (0.88) | PDE5APDE6C | |
| Gisadenafil SCHEMBL3585141 | 0.94 | PDE5A (0.87) | PDE5APDE6C | |
| Gisadenafil SCHEMBL29379724 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL120995 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL6199327 | 0.90 | PDE5A (0.89) | PDE5APDE6C | |
| SCHEMBL3579657 | 0.90 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL3576608 | 0.90 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL4559199 | 0.89 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL3584023 | 0.89 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6767921 | 0.89 | PDE5A (0.90) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | claimed |
| EP-3575791-B1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY INC (JP) | 2024-01-10 | — | — | EP | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| CN-110547288-A | Blood processing method and blood collection tube | ARKRAY INC | 2019-12-10 | — | — | CN | disclosed |
| EP-3575791-A1 | BLOOD TREATMENT METHOD AND BLOOD COLLECTION TUBE | ARKRAY, Inc. (JP) | 2019-12-04 | — | — | EP | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PFIZER INC | 2006-12-28 | — | — | US | disclosed |
| EP-1220856-B1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040152712-A1 | Pharmaceutically active compounds | PFIZER INC. | 2004-08-05 | — | — | US | disclosed |
| US-6677335-B1 | PYRAZOLO(4,3-D)PYRIMIDIN-7-ONE DERIVATIVES; CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; SEXUAL AND UROGENITAL DISORDERS | PFIZER INC | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 28/4885 |
| US-20060293347-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 28/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | PDE5A 39/4885PDE6C 382/4885 |
| US-20040152712-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.